These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29051077)

  • 21. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.
    Stifter S; Babarović E; Valković T; Seili-Bekafigo I; Stemberger C; Nacinović A; Lucin K; Jonjić N
    Diagn Pathol; 2010 May; 5():30. PubMed ID: 20482792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
    Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
    Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
    Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
    Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study.
    Chu B; Wang YT; Gao S; Shi L; Lu MQ; Fang LJ; Xiang QQ; Chen Y; Wang MZ; Wang LF; Sun K; Yang J; Duan F; Bao L
    Ann Hematol; 2024 Sep; 103(9):3677-3690. PubMed ID: 38955826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
    Mellors PW; Binder M; Ketterling RP; Greipp PT; Baughn LB; Peterson JF; Jevremovic D; Pearce KE; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Kapoor P; Gonsalves WI; Hwa YL; Fonder A; Hobbs M; Kourelis T; Warsame R; Lust JA; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2020 May; 4(10):2236-2244. PubMed ID: 32442300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Robust isolation of malignant plasma cells in multiple myeloma.
    Frigyesi I; Adolfsson J; Ali M; Christophersen MK; Johnsson E; Turesson I; Gullberg U; Hansson M; Nilsson B
    Blood; 2014 Feb; 123(9):1336-40. PubMed ID: 24385542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
    Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
    Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
    Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
    Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
    Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
    Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.
    Martello M; Remondini D; Borsi E; Santacroce B; Procacci M; Pezzi A; Dico FA; Martinelli G; Zamagni E; Tacchetti P; Pantani L; Testoni N; Marzocchi G; Rocchi S; Zannetti BA; Mancuso K; Cavo M; Terragna C
    Leukemia; 2016 Sep; 30(9):1869-76. PubMed ID: 27074969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substratification of patients with newly diagnosed standard-risk multiple myeloma.
    Binder M; Rajkumar SV; Ketterling RP; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
    Br J Haematol; 2019 Apr; 185(2):254-260. PubMed ID: 30768679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma.
    Atrash S; Robinson M; Taneja A; Paul B; Cassetta K; Ndiaye A; Varga C; Block J; Lipford EH; Smith ET; McCall CM; Thurston V; Foureau D; Usmani SZ; Voorhees PM; Bhutani M
    Eur J Haematol; 2023 Sep; 111(3):373-381. PubMed ID: 37311695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double CD38
    Mykytiv V; Alwaheed A; Mohd Hashim NA
    Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma.
    Baldus SE; Palmen C; Thiele J
    Histol Histopathol; 2007 Aug; 22(8):889-93. PubMed ID: 17503346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
    Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
    Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
    Aref S; Goda T; El-Sherbiny M
    Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma].
    Zhao YR; Fu R; Guan J; Gao S; Liu H; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Wang HQ; Xing LM; Wang J; Li LJ; Shao ZH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):274-7. PubMed ID: 22781716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.